Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer

Abstract

The management of high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) continues to be a serious clinical problem. The role of many factors related to efficacy of Bacillus Calmette-Guérin (BCG), which is the most useful intravesical agent for these tumors, is still unknown. This study investigated the prognostic value of tumor location in high-grade non-muscle-invasive bladder cancer. Seventy-four patients with HG non-muscle-invasive bladder cancer, without carcinoma in situ (CIS), were treated by transurethral resection of bladder tumor (TURBT). Twenty-eight patients received adjuvant BCG therapy after TURBT. The relation between tumor location and the recurrence capacity was estimated using a Cox regression model. Our results suggest that tumor location is an important prognostic factor for BCG-therapy response in patients with high-grade non-muscle-invasive bladder cancer. Tumors in the bladder neck might have a higher risk of recurrence after intravesical immunotherapy. In addition, tumors in the lateral and posterior bladder walls might be at higher risk of recurrence when treated by TURBT alone.

Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer

“…Even in patients with bladder cancer, the impact of tumor location on prognosis is still controversial. Vukomanovic et al showed that tumor location is a prognostic factor for recurrence in patients with high-grade NMIBC [39], while study from Deng et al indicated that tumor location may not be suitable to predict the recurrence of NMIBC [40]. Our study suggested that the prognostic significance of tumor location in NMIBC is depend on SC markers expression status.…”

Prediction models for progression of non‐muscle‐invasive bladder cancer: A review

“…At present, three risk models are widely known for prediction of the risk of tumor recurrence and progression of NMIBC: the EORTC risk tables, the CUETO scoring model and the new EORTC model . Some previous studies, including ours, have shown that another predictor of tumor recurrence or progression is tumor location, especially those with BNI …”

Impact of a surgeon on the relapse-free survival of patients with non-muscle-invasive bladder cancer

“…Rouprêt и соавт. оценили результаты 340 ТУР по поводу РМПБМИ в стадии pT1 и выявили значи-мые различия в частоте обнаружения мышечной ткани в удаленном препарате между более молодыми и опыт-ными хирургами (61,3 % против 73,8 %; p = 0,02) [11]. Однако по данным мультивариантного анализа только небольшой опыт хирурга вне зависимости от наличия или отсутствия мышечной ткани в препарате повышал риск рецидива (ОР 2,33; 95 % ДИ 1,45-3,74; p = 0,01).…”

“…Рак мочевого пузыря в области треугольника [10] или шейки [11] мочевого пузыря. Тем не менее немногочисленность исследова-ний и вариабельность результатов этих работ обуслов-ливают дискутабельность прогностической роли дан-ного фактора, что подтверждается его отсутствием в общепринятых прогностических классификациях РМПБМИ [1,12,13]; 4) необходимо согласиться, что травматичность и частота осложнений операции являются одними из важных компонентов оценки ее результатов.…”